Clinical Trials on Psoriasis Nail in South Africa

Total 257 results

AbbVie

Active, not recruiting

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) (SELECT - PsA 1)

Psoriatic Arthritis

United States, Argentina, Australia, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic... and more
Coherus Biosciences, Inc.
Shire

Completed

Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)

Plaque Psoriasis

United States, Israel, Australia, Germany, South Africa, Poland, Canada
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis

Psoriatic Arthritis

France, Belgium, Korea, Republic of, Netherlands, United Kingdom, Germany, Taiwan, Portugal, Denmark, Saudi Arabia, Czechia, Sweden, Switzerland, Argentina, Poland, Italy, Hungary, Spain, Australia, Austria, Colombia, Finland, Former... and more
Zai Lab (Hong Kong), Ltd.
Zai Lab (US) LLC

Recruiting

A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis

Plaque Psoriasis

Australia
Opal Rheumatology Ltd.
Merck Sharp & Dohme LLC

Unknown

Investigating the Utilisation and Effectiveness of Originator and Biosimilar Anti-TNF Agents

Rheumatoid Arthritis | Psoriatic Arthritis | Ankylosing Spondylitis

Australia
Amgen

Completed

Study to Assess the Injection Site Pain Associated With a New Etanercept Formulation in Adults With Rheumatoid Arthritis or Psoriatic Arthritis

Arthritis, Rheumatoid; Arthritis, Psoriatic

United States, Puerto Rico
Janssen Pharmaceutica N.V., Belgium

Completed

A Study on Assessment of STELARA and Tumor Necrosis Factor Alpha Inhibitor Therapies in Participants With Psoriatic Arthritis (PsaBio)

Psoriatic Arthritis

France, United Kingdom, Belgium, Spain, Netherlands, Greece, Russian Federation
Boehringer Ingelheim

Completed

A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis

Generalized Pustular Psoriasis

Spain, Taiwan, Thailand, Korea, Republic of, Germany, Malaysia, United States, Argentina, Belgium, Chile, China, France, Greece, Italy, Japan, Mexico, Netherlands, Philippines, Russian Federation, South Africa, Tunisia, Turkey, Vietnam
Alumis Inc

Active, not recruiting

Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis

Plaque Psoriasis

United States, Canada
Atridia Pty Ltd.

Completed

A Study of SHR-1314 in Healthy Subjects

Psoriasis

Australia
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis

Psoriasis

United States, Hong Kong, Canada, South Africa
Amgen

Completed

Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA) (PALACE4)

Psoriatic Arthritis

United Kingdom, Belgium, United States, Canada, Australia, Taiwan, Czechia, Russian Federation, Hungary, Poland, Korea, Republic of, Italy, New Zealand, France, Bulgaria, Estonia, Romania, Lithuania
Novartis Pharmaceuticals

Completed

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis (FUTURE 4)

Arthritis, Psoriatic

United States, Italy, Germany, Australia, Belgium, Poland, Bulgaria, Russian Federation, Czechia, Canada, France, Sweden, United Kingdom
Bausch Health Americas, Inc.

Terminated

Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis (AMVISION-1)

Psoriatic Arthritis

United States, Italy, Spain, Hungary, Belgium, Mexico, Poland, Switzerland, United Kingdom, Russian Federation, Canada, Greece, France, Bulgaria, Slovakia, Estonia, Czech Republic
Bristol-Myers Squibb

Active, not recruiting

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

Psoriatic Arthritis

Russian Federation, United States, Argentina, Australia, Brazil, Bulgaria, Chile, China, Colombia, Czechia, Finland, France, Hungary, Ireland, Italy, Mexico, Poland, Romania, Spain, Taiwan, United Kingdom
Glenmark Pharmaceuticals Ltd. India

Completed

To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis

Scalp Psoriasis

United States
Sandoz
Hexal AG

Completed

Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Etanercept (GP2015) and Enbrel (EGALITY)

Chronic Stable Plaque Psoriasis

Germany, Romania, Bulgaria, Czech Republic, Estonia, Hungary, Poland, Russian Federation, Slovakia, South Africa, Ukraine, United Kingdom
Amgen

Completed

Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis. (FOREMOST)

Arthritis, Psoriatic

United States, Spain, Netherlands, Canada, France, Russian Federation, Belgium, Austria, Germany, Italy, United Kingdom
Therapeutics, Inc.

Completed

A Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis (305)

Plaque Psoriasis

United States
Alumis Inc

Completed

A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis

Plaque Psoriasis

United States, Canada, Czechia
Creabilis SA

Completed

Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris

Psoriasis Vulgaris

United States, United Kingdom
Maruho Co., Ltd.

Completed

Study to Investigate the Efficacy and the Safety of M518101 in Plaque Psoriasis Patients

Plaque Psoriasis

United States
AbbVie

Active, not recruiting

A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) (SELECT - PsA 2)

Psoriatic Arthritis

United States, Belgium, Brazil, Canada, Chile, Czechia, France, Greece, Hungary, Italy, Japan, Netherlands, New Zealand, Portugal, Puerto Rico, Spain, United Kingdom
Coherus Biosciences, Inc.

Completed

Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis (PsOsim)

Plaque Psoriasis

United States, Canada, Bulgaria, Chile, Croatia, Estonia, Georgia, Israel, Italy, Latvia, Moldova, Republic of, Poland, Russian Federation, Slovakia, South Africa, Ukraine
AbbVie

Recruiting

A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)

Moderate Plaque Psoriasis

United States, Puerto Rico, Canada, Australia
Vitae Pharmaceuticals, Inc.

Terminated

AGN-242428 in the Treatment of Plaque Psoriasis

Plaque Psoriasis

United States
Moberg Pharma AB

Active, not recruiting

A Vehicle-controlled Study of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO)

Onychomycosis

United States, Canada
Bausch Health Americas, Inc.
Dow Pharmaceutical Sciences

Completed

Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis

Plaque Psoriasis

United States
Bausch Health Americas, Inc.
Dow Pharmaceutical Sciences

Completed

Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis

Plaque Psoriasis

United States
BioFactura Australia Pty Ltd.
Avance Clinical Pty Ltd.

Completed

Bioequivalence Phase I Study of BFI-751 Compared With EU and US-STELARA® in Healthy Adults

Psoriasis

Australia, New Zealand
Akros Pharma Inc.

Terminated

Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis (CLEAR-PS)

Skin Diseases | Plaque Psoriasis

United States, Canada
Arcutis Biotherapeutics, Inc.

Completed

Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis

Plaque Psoriasis

United States, Australia, Bulgaria, Canada
Akros Pharma Inc.

Completed

Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis (IMPACT-PS)

Skin Diseases | Psoriasis | Plaque Psoriasis

United States, Canada, Poland
Bristol-Myers Squibb

Recruiting

A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis

Palmoplantar Psoriasis | Genital Psoriasis

United States, Germany, Spain, Italy, Poland, Argentina, Canada
Bristol-Myers Squibb

Terminated

Study of BMS-587101 in Patients With Moderate to Severe Psoriasis

Psoriasis, Moderate to Severe

United States
Bausch Health Americas, Inc.

Completed

Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis

Onychomycosis

United States, Dominican Republic
Sun Pharmaceutical Industries Limited

Completed

Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis

Scalp Psoriasis

United States, Australia
Halcygen Pharmaceuticals Limited

Completed

Study Comparing SUBA™-Itraconazole With SPORANOX® (Itraconazole) in the Treatment of Onychomycosis

Onychomycosis

United States
Jiangsu HengRui Medicine Co., Ltd.

Completed

Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis

Moderate-to-severe Chronic Plaque Psoriasis

United States, Australia, China
AbGenomics B.V Taiwan Branch

Completed

Phase IIa Study of Multiple Doses of AbGn-168H by iv Infusion in Moderate to Severe Chronic Plaque Psoriasis Patients (AbGn-168H)

Moderate to Severe Chronic Plaque Psoriasis

United States
Glenmark Pharmaceuticals Ltd. India

Completed

To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis).

Psoriasis Vulgaris

United States
Hangzhou Highlightll Pharmaceutical Co., Ltd

Recruiting

The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis

Plaque Psoriasis

United States
University of Sheffield
The Psoriasis and Psoriatic Arthritis Alliance

Completed

The Effectiveness of a Mindful Parenting Intervention for Parents of Children With Psoriasis and Parents of Children With Eczema

Stress | Psoriasis | Eczema

United Kingdom
Evelo Biosciences, Inc.

Completed

A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis

Psoriasis | Plaque Psoriasis

United Kingdom, Hungary, Poland, United States
Stiefel, a GSK Company
GlaxoSmithKline

Completed

Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of the Toenail.

Onychomycosis

United States, South Africa, Canada, Dominican Republic, Ecuador, Honduras, Panama
Amgen

Recruiting

A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis

Plaque Psoriasis

United States
Janssen Research & Development, LLC

Active, not recruiting

Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis (VISIBLE)

Plaque Psoriasis | Scalp Psoriasis

United States, Canada
Galderma R&D

Completed

Plaque Psoriasis Study in Pediatric Subjects

Plaque Psoriasis

United States, Spain, Germany, Italy, Belgium, Canada, Hungary
Eli Lilly and Company

Completed

A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis (IXORA-Q)

Psoriasis | Genital Psoriasis

Turkey, Puerto Rico, United States, Australia, Belgium, Austria, Netherlands, Canada
UCB Biopharma S.P.R.L.

Completed

A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) (CIMPASI-2)

Psoriasis | Plaque Psoriasis

United States, Austria, Canada, Poland

Clinical Trials on Psoriasis Nail in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Portugal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations